IL17A and psoriasis vulgaris: While most of them are still in clinical development, the IL-17R-blocking MoAb brodalumab has been recently cleared by FDA for moderate to severe plaque psoriasis (79), and the IL-17-binding MoAb secukinumab has been approved for moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis (80).